Department of Surgery, Surgical Outcomes Analysis and Research, University of Massachusetts Medical School, 55 Lake Avenue North, Suite S3-752, Worcester, MA 01655, USA.
J Gastrointest Surg. 2010 Nov;14(11):1701-8. doi: 10.1007/s11605-010-1326-4. Epub 2010 Sep 16.
Distinct outcome measures such as in-hospital and 30-day mortality have been used to evaluate pancreatectomy results. We posited that these measures could be compared using national data, providing more precision for evaluating published outcomes after pancreatectomy.
Patients undergoing resection for pancreatic cancer were identified from the linked SEER-Medicare databases (1991-2002). Mortality was analyzed and trend tests were utilized to evaluate risk of death within ≤60 days of resection and from 60 days to 2 years post-resection. Univariate analysis assessed patient characteristics such as race, gender, marital status, socioeconomic status, hospital teaching status, and complications.
One thousand eight hundred forty-seven resected patients were identified: 7.7% (n = 142) died within the first 30 days, 83.6% of whom died during the same hospitalization. Postoperative in-hospital mortality was 8.1% (n = 150), 79% of which was within 30 days, greater than 90% of which was within 60 days. Risk of death decreased significantly over the first 60 days (P < 0.0001). After 60 days, the risk did not decrease through 2 years (P = 0.8533). Univariate analysis showed no difference between the two groups in terms of race, gender, marital status, and socioeconomic status, but patients dying within 60 days were more likely to have experienced a complication (41.1% vs. 17.0%, P < 0.0001).
In-hospital and 30-day mortality after resection for cancer are similar nationally; thus, comparing mortality utilizing these measures is acceptable. After a 60-day post-resection window of increased mortality, mortality risk then continues at a constant rate over 2 years, suggesting that mortality after pancreatectomy is not limited to early ("complication") and late ("cancer") phases. Determining ways to decrease perioperative mortality in the 60-day interval will be critical to improving overall survival.
不同的预后评估指标,如住院期间和 30 天死亡率,已被用于评估胰腺切除术的结果。我们假设可以使用全国性数据比较这些指标,从而为评估胰腺切除术后的已发表结果提供更准确的信息。
从 SEER-Medicare 数据库(1991-2002 年)中确定接受胰腺切除术的患者。分析死亡率并进行趋势检验,以评估术后 60 天内和术后 60 天至 2 年内死亡的风险。单变量分析评估了患者的特征,如种族、性别、婚姻状况、社会经济状况、医院教学状况和并发症。
共确定了 1847 例接受切除术的患者:30 天内死亡率为 7.7%(n=142),其中 83.6%的患者在住院期间死亡。术后院内死亡率为 8.1%(n=150),其中 79%发生在术后 30 天内,90%以上发生在术后 60 天内。术后 60 天内死亡风险显著降低(P<0.0001)。术后 60 天后,2 年内死亡风险未降低(P=0.8533)。单变量分析显示,两组患者在种族、性别、婚姻状况和社会经济状况方面无差异,但在术后 60 天内死亡的患者更有可能发生并发症(41.1%比 17.0%,P<0.0001)。
全国范围内,癌症切除术后的院内和 30 天死亡率相似;因此,使用这些指标比较死亡率是可以接受的。在术后 60 天的高死亡率窗口期之后,死亡率风险在 2 年内以恒定的速度继续增加,这表明胰腺切除术后的死亡率不仅限于早期(“并发症”)和晚期(“癌症”)阶段。确定如何降低术后 60 天内的围手术期死亡率对于提高总体生存率至关重要。